NCT07029412View on ClinicalTrials.gov

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

December 22, 2025

Study Completion Date

January 26, 2026

Conditions
Postbariatric Hypoglycemia
Interventions
DRUG

MBX 1416 (INN imapextide)

A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.

Trial Locations (4)

28557

RECRUITING

MBX Biosciences Investigational Site, Morehead City

37920

RECRUITING

MBX Biosciences Investigational Site, Knoxville

78229

RECRUITING

MBX Biosciences Investigational Site, San Antonio

80045

RECRUITING

MBX Biosciences Investigational Site, Aurora

Sponsors

Lead Sponsor

MBX Biosciences
All Listed Sponsors
lead

MBX Biosciences

INDUSTRY

NCT07029412 - Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) | Biotech Hunter | Biotech Hunter